This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Mylotarg™​​​​​​​​​​​​​​ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.

Efficacy and Safety video: Data from the ALFA-0701 study

Duration: 06:12

Speaker: Professor Robert Hills

In this video, Professor Hills discusses the pivotal, randomised study for Mylotarg in the treatment of Acute Myeloid Lekaemia with clear explanations on the dosing and schedule in combination with daunorubcin and cytarabine.  He also mentions the results of the study in terms of event free survival, persistence of benefit and reduction of relapse.  The Adverse Events seen in both arms are also discussed.

Robert Hills is Professor of Medical Statistics at Nuffield Department of Population Health, Oxford. Prior to this role, Robert was Professor of Translational Statistics at the Centre for Trials at Cardiff University, where he was lead for haematological malignancies and Deputy Director of the Cancer Division​​​​​​. He has been a statistician for the National Cancer Research Institute acute myeloid leukaemia trials for over 15 years and works on developing methodologies to make novel treatments available to patients within a trial setting.  He has worked on meta-analyses of clinical trials in cancer for over 20 years and recently coordinated the individual patient data meta-analysis of gemtuzumab ozogamicin: updated and expanded results are currently in preparation for publication.

Explore more

Download the fast facts PDF document to aid your understanding of MYLOTARG

Download the pdf

AML, Acute Myeloid Leukaemia

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

PP-MYL-GBR-0237. March 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Understand the evidence


For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020